Plasma renin activity and risk of cardiovascular and mortality outcomes among individuals with elevated and nonelevated blood pressure

Simran K. Bhandari 1,*, Michael Batech 2, Jiaxiao Shi 2, Steven J. Jacobsen 2, John J. Sim 1

1 Division of Nephrology and Hypertension, Department of Internal Medicine, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, USA
2 Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA

Article history:
Received 12 June 2016
Received in revised form
16 July 2016
Accepted 20 July 2016
Available online 26 July 2016

Keywords:
Cardiovascular outcomes
Epidemiology
Mortality
Plasma renin activity

A B S T R A C T

Background: We sought to evaluate plasma renin activity (PRA) levels and risk of mortality and cardiovascular events among individuals with elevated blood pressure [systolic blood pressure (SBP) ≥ 140 mmHg] and those with controlled blood pressure (SBP < 140 mmHg) in a large diverse population.

Methods: A retrospective cohort study between January 1, 2007, and December 31, 2013, among adults (≥ 18 years) within an integrated health system was conducted. Subjects were categorized by SBP into 2 groups: SBP < 140 mmHg and SBP ≥ 140 mmHg and then further categorized into population-based PRA tertiles within each SBP group. Cox proportional hazard modeling was used to estimate hazard ratios for cardiovascular and mortality outcomes among tertiles of PRA levels.

Results: Among 6,331 subjects, 32.6% had SBP ≥ 140 mmHg. Multivariable hazard ratios and 95% confidence interval for PRA tertiles T2 and T3 compared to T1 in subjects with SBP ≥ 140 mmHg were 1.42 (0.99 to 2.03) and 1.61 (1.12 to 2.33) for ischemic heart events; 1.40 (0.93 to 2.10) and 2.23 (1.53–3.27) for congestive heart failure; 1.10 (0.73–1.68) and 1.06 (0.68–1.66) for cerebrovascular accident; 1.23 (0.94–1.59) and 1.43 (1.10–1.86) for combined cardiovascular events; and 1.39 (0.97–1.99) and 1.35 (0.92–1.97) for all-cause mortality, respectively. Among the SBP < 140 mmHg group, there was no relationship between PRA levels and outcomes.

Conclusion: Higher PRA levels demonstrated increased risk for ischemic heart events and congestive heart failure and a trend toward higher mortality among individuals with SBP ≥ 140 mmHg but not among those with SBP < 140 mmHg.

Introduction

Using plasma renin activity (PRA) levels in clinical practice may provide insights into hypertension (HTN) and help improve cardiovascular and mortality outcomes [1]. PRA is a surrogate of renin—angiotensin system (RAS) activity and potentially serves as a biomarker for increased risk for cardiovascular events and mortality in the congestive heart failure (CHF), ischemic heart disease (IHD), and HTN populations...
Methods

A retrospective, longitudinal cohort study of Kaiser Permanent Southern California (KPSC) members was performed between January 1, 2007, and December 31, 2013. KPSC is a prepaid integrated health system providing comprehensive care to over 3.9 million members throughout Southern California, from Bakersfield to San Diego at 13 medical centers and over 200 satellite clinics. As of December 2010, there were over 2.5 million adult members within KPSC. The patient population is racially, ethnically, and socioeconomically diverse, reflecting both the general population of the practicing area and the overall population in the state of California.

All KPSC members have similar benefits and access to healthcare services, clinic visits, procedures, copays for medications, and deductibles for health care. Complete health-care encounters are tracked using a common electronic health record from which all study information was extracted. All data for this study were collected as part of routine clinical encounters where health-care providers determined the need for laboratory measurements, procedures, and medications. The study protocol was reviewed and approved by the KPSC Institutional Review Board and was exempt from informed consent.

Individuals 18 years or older with HTN and at least 1 documented outpatient measurement of PRA were identified in the study period between January 1, 2007, and December 31, 2011 (Fig. 1). Individuals were followed until they experienced any outcome, for up to 2 years following PRA measurement date, or until the end of the observation period (December 31, 2013). Individuals had to have a minimum of 1 outpatient blood pressure measurement available within 30 days of PRA measurement to be included in the study cohort. In addition, all individuals were required to have 1-year continuous membership (with no more than a 45-day gap) in the health-care plan before the serum PRA measurement to accurately capture any comorbidities. To eliminate confounding of comorbidities on incidence/outcomes, individuals were excluded if they had prevalent coronary artery disease, CHF, and cerebrovascular disease which were determined by inpatient and outpatient International Classification of Diseases (ICD) diagnosis coding. Patients who had previous procedural coding for coronary artery bypass grafting and percutaneous coronary intervention were also excluded from the study population. To eliminate confounding from volume accumulation on blood pressure present within the end-stage renal disease (ESRD) population, we excluded all ESRD patients. Patients with a diagnosis of renovascular disease (ICD-9 code 405.9/ICD-10 I115.0) were also excluded. Patients with hyperaldosteronism were not excluded from the study population.

Data collection

All laboratory data, vital sign assessments (including blood pressure measurements), and diagnostic studies and procedures are collected and stored in the KPSC electronic health record as part of routine clinical care encounters. All laboratory measurements are performed and reported from an American College of Pathology/Clinical Laboratory Improvement Act–certified laboratory. All baseline laboratory values reported were those obtained within 60 days of PRA measurement. If multiple laboratory values were available, value closest to the date of PRA measurement was used for analysis. Comorbidities, including diabetes mellitus, coronary artery disease, CHF, and cerebrovascular disease, were assessed based on inpatient and outpatient ICD-9 diagnosis coding. CKD was identified and defined as an estimated glomerular filtration rate of less than 60 mL/min/1.73 m² estimated from serum creatinine levels using the Chronic Kidney Disease Epidemiology Collaboration Equation [21]. ESRD, defined as maintenance hemodialysis, peritoneal dialysis, or renal transplantation, was identified from electronic medical records, procedure coding data, Medicare Form 2728, and internal information from the KPSC Renal Program Administration. Data on hospitalizations and diagnoses that occurred outside the
health-care system were available through administrative billing and claims records.

Antihypertensive medication use was retrieved from KPSC internal pharmacy dispensing records. Prescription orders, pharmacy fills, and refills are tracked for KPSC members with pharmacy benefits, which accounts for over 95% of members. Individuals were determined to be on antihypertensive medication if it was prescribed and dispensed within 90 days before the PRA measurement date. They were considered to be taking concomitant antihypertensive medications if there was a greater than 7-day overlap in medications. Medications that were prescribed and filled for less than 7 days were not considered as being on treatment with those particular medications. Single-pill combination drugs were classified into their different respective components. The total number of blood pressure medications was defined by the number of different antihypertensive medications taken by each subject and may have included multiple medications from the same drug class. Antihypertensive medications were further categorized as diuretics/natriuretics (i.e., mineralocorticoid receptor blockers, thiazide diuretics, calcium channel blockers, loop diuretics), RAS blockers (angiotensin-converting enzyme inhibitors and angiotensin receptor blockers), or RAS suppressors (β-blockers, centrally acting α-agonists, methyldopa, and direct renin inhibitors).

PRA measurement and blood pressure measurement

All PRA measurements were made with an enzyme kinetic assay that quantifies angiotensin I generation by radioimmunoassay in an American College of Pathology/CLIA–certified laboratory. The PRA test was performed by Quest Diagnostics Nichols Institute using the Sealey PRA assay [22]. PRA values are reported as ng/mL/h. PRA values were single measurements obtained during routine outpatient clinical encounters for various indications as determined by individual health-care practitioners. PRA values at the highest and lowest 0.5 percentiles and those done in the inpatient setting were excluded. There was no standardization of predraw activity, and measurements were obtained at varying times throughout the day. For subjects with multiple PRA values, the first value in the study period was used and all data were relative to that date. Sensitivity analyses were performed for those with multiple PRA values using the arithmetic mean values of PRA. Subjects were categorized into tertiles according to PRA levels and SBP (< 140 mmHg and ≥ 140 mmHg). Blood pressure measurements throughout KPSC are performed in a standardized manner, which has previously been shown to result in a high level of reliability [23]. All providers who perform blood pressure measurements are trained to have individuals seated with both feet on the ground for 3–5 minutes, arms supported
at heart level, and patients are instructed to refrain from talking during the measurements. An automated aneroid sphygmomanometer is used to perform all measurements.

**Outcomes**

The primary outcomes evaluated were cardiovascular events and all-cause mortality as separate competing outcomes. Cardiovascular events included any incident ischemic heart event (IHE), CHF event, and cerebrovascular event (CED). Any hospitalization with the primary or secondary diagnoses of IHE, CHF, and CED was used to identify these outcomes (Supplemental Table 1). The IHE was defined as any code for myocardial infarction, angina, coronary occlusion, myocardial necrosis, and any procedure codes for percutaneous coronary intervention or coronary artery bypass grafting. CHF was defined as any hospitalization for heart failure and cardiomyopathy. CED was defined as stroke, central nervous system bleed, or cerebrovascular disease/accident not otherwise specified. Mortality information for the cohort was obtained from a comprehensive database that combines 6 data sources including California State Death Master Files, California State Multiple Cause of Death Master Files, Social Security Administration, Death Master Files, KPSC Hospital and Emergency Department records, KPSC Membership System, KPSC Perinatal Data Mart, and Outside Claims Processing System. Individuals were followed until the occurrence of that particular event, disenrollment from the health plan, or for up to 2 years following the PRA measurement date. Follow-up was not censored when another event occurred, with the exception of death. Each outcome was also followed up separately without competing outcomes as part of a sensitivity analysis.

**Statistical analyses**

Individuals included for analysis were categorized by SBP into 2 groups: (1) SBP < 140 mmHg and (2) SBP ≥ 140 mmHg. The demographic characteristics and comorbidities of individuals with SBP < 140 mmHg were compared to those with SBP ≥ 140 mmHg. The chi-square or Fisher exact test was used for comparison of categorical variables and t test or Kruskal–Wallis tests were used for continuous variables, as appropriate; the Shapiro–Wilk test was used for normality assumptions. Subjects were further categorized into population-based PRA tertiles based on their SBP group. In subjects with SBP < 140 mmHg, PRA tertiles were 0–0.90 (T1), 0.91–2.66 (T2), and > 2.66 (T3). For SBP > 140 mmHg, PRA tertiles were 0–0.55 (T1), 0.56–1.90 (T2), and > 1.90 (T3). Event rates were determined within each PRA tertile for both SBP groups. The primary analysis was to evaluate different levels of PRA and the risk of IHE, CHF, CED, combined cardiovascular events, and all-cause mortality among those with (1) SBP < 140 mmHg and (2) SBP ≥ 140 mmHg separately. Within each PRA tertile, IHE, CHF, CED, combined cardiovascular events, and all-cause mortality rates were calculated. Unadjusted and multivariable Cox proportional hazards models were used to examine the relationship between PRA levels and incident IHE, CHF, CED, combined cardiovascular events, and mortality with the lowest tertile (T1) used as the reference range in each SBP group. Multivariable hazard ratios (HRs) were calculated with adjustment for potential confounders including age, sex, race/ethnicity, Charlson comorbidity index, and use of diabetic and antihypertensive medication (including RAS inhibitors, RAS blockers, diuretics/natriuretics). All statistical analyses were generated using the SAS statistical software (version 9.2; SAS Institute, Cary, NC, USA). All tests were 2 sided and considered significant at the 5% type I error rate.

**Results**

**Cohort characteristics**

A total of 6,331 individuals were identified for inclusion in the study cohort (Fig. 1). The PRA levels of the cohort and by SBP categories demonstrated a Poisson distribution (Fig. 2). PRA levels ranged from undetectable to as high as 58.8 ng/mL/h. The median PRA level was 1.4 ng/mL/h for the entire study cohort.

The mean age of the study population was 55.4 years, with women accounting for 62.1%. The racial/ethnic composition of the PRA cohort was with 40% whites, 23% Hispanics, 22% blacks, and 11% Asians (Table 1). Diabetes mellitus was present in 20.9% with a mean hemoglobin A1c level of 6.8 (Supplemental Table 2). The mean estimated glomerular filtration rate was 81 mL/min/1.73 m² for the study cohort and CKD was present in 16.8% (Table 1). Diagnosed HTN was prevalent in 75.3% of the study cohort. The mean blood pressure of the cohort was 134/77 mmHg. Diuretics/natriuretics were the most frequently used medication class, accounting for 74% of the cohort.

SBP ≥ 140 mmHg accounted for 32.6% of the PRA study cohort, with the average blood pressure in this group being 156/85 mmHg. In the remaining cohort with SBP < 140 mmHg, the mean blood pressure was 123/73 mmHg. The individuals in the SBP > 140 mmHg group were more frequently male (44% vs. 35%), more likely to be black (26% vs. 20%), and had greater overall usage of all antihypertensive medication classes (Table 1). Compared with the SBP < 140 mmHg population, the SBP ≥ 140 mmHg population had a greater prevalence of comorbid conditions including CKD (20.9% vs. 14.8%), greater usage of diabetic medications (28% vs. 24%), and a greater

**Figure 2. Distribution of plasma renin activity by systolic blood pressure at baseline.** The PRA levels of the cohort by SBP categories demonstrated a Poisson distribution. PRA levels ranged from undetectable to as high as 58.8 ng/mL/h. The median PRA level was 1.40 ng/mL/h for the entire cohort study.

PRA, plasma renin activity; SBP, systolic blood pressure.
Table 1. Study population characteristics by categories of blood pressure at the time of PRA measurement

| Variable                        | SBP < 140 mmHg, n = 4,268 (67.4) | SBP ≥ 140 mmHg, n = 2,063 (32.6) | Total, N = 6,331 | P          |
|---------------------------------|-----------------------------------|-----------------------------------|------------------|------------|
| **PRA (ng/mL/h)**               |                                   |                                   |                  | < 0.001    |
| N                               | 4,268                             | 2,063                             | 6,331            |            |
| Mean (SD)                       | 4.0 (6.89)                        | 2.6 (4.92)                        | 3.5 (6.35)       |            |
| Median                          | 1.5                               | 1.1                               | 1.4              |            |
| Range                           | 0.0–58.8                          | 0.0–58.5                          | 0.0–58.8         | 0.204      |
| **Age at index date (y)**       |                                   |                                   |                  |            |
| N                               | 4,268                             | 2,063                             | 6,331            |            |
| Mean (SD)                       | 55.3 (15.45)                      | 55.5 (16.79)                      | 55.4 (15.90)     |            |
| Median                          | 58                                | 58                                | 57               |            |
| Range                           | 18.0–94.0                         | 18.0–96.0                         | 18.0–96.0        |            |
| **Patient sex, n (%)**          |                                   |                                   |                  | < 0.001    |
| Female                          | 2,769 (64.9)                      | 1,164 (56.4)                      | 3,933 (62.1)     |            |
| Male                            | 1,499 (35.1)                      | 899 (43.6)                        | 2,398 (37.9)     |            |
| **Race/ethnicity, n (%)**       |                                   |                                   |                  | < 0.001    |
| Asian, non-Hispanic             | 479 (11.2)                        | 211 (10.2)                        | 690 (10.9)       |            |
| Black, non-Hispanic             | 844 (19.8)                        | 531 (25.7)                        | 1,375 (21.7)     |            |
| Hispanic                        | 985 (23.1)                        | 477 (23.1)                        | 1,462 (23.1)     |            |
| Other, non-Hispanic             | 170 (4.0)                         | 98 (4.8)                          | 268 (4.2)        |            |
| White, non-Hispanic             | 1,790 (41.9)                      | 746 (36.2)                        | 2,536 (40.1)     |            |
| **Charlson comorbidity index, n (%)** |                                   |                                   |                  |            |
| 0                               | 2,075 (48.7)                      | 1,004 (48.8)                      | 3,079 (48.8)     | 0.001      |
| 1–2                             | 1,708 (40.1)                      | 764 (37.1)                        | 2,472 (38.1)     |            |
| 3 or more                       | 474 (11.1)                        | 290 (14.1)                        | 764 (12.1)       |            |
| **Baseline SBP (mmHg)**         |                                   |                                   |                  | < 0.001    |
| N                               | 4,268                             | 2,063                             | 6,331            |            |
| Mean (SD)                       | 123.1 (11.85)                     | 155.7 (15.06)                     | 133.7 (20.05)    |            |
| Median                          | 125                               | 151                               | 132              |            |
| Range                           | 63.0–139.0                        | 140.0–240.0                       | 63.0–240.0       |            |
| **Baseline DBP (mmHg)**         |                                   |                                   |                  | < 0.001    |
| N                               | 4,268                             | 2,063                             | 6,331            |            |
| Mean (SD)                       | 72.6 (10.32)                      | 85.3 (13.74)                      | 76.7 (12.99)     |            |
| Median                          | 73                                | 85                                | 76               |            |
| Range                           | 32.0–104.0                        | 8.0–144.0                         | 8.0–144.0        |            |
| **Prevalent hypertension, n (%)** | 2,953 (69.2)                      | 1,815 (88)                        | 4,768 (75.3)     | < 0.001    |
| **Prevalent diabetes mellitus, n (%)** | 869 (20.4)                      | 455 (22.1)                        | 1,324 (20.9)     | 0.030      |
| Chronic kidney disease, n (%)   | 630 (14.8)                        | 432 (20.9)                        | 1,062 (16.8)     | < 0.001    |
| No chronic kidney disease, n (%) | 3,638 (85.2)                      | 1,631 (79.1)                      | 5,269 (83.2)     |            |
| **Antihypertensive medication use, n (%)** | 2,179 (51.1)                      | 1,452 (70.4)                      | 3,631 (57.4)     | < 0.001    |
| RAS suppressors                  | 2,352 (55.1)                      | 1,541 (74.7)                      | 3,893 (61.5)     | < 0.001    |
| RAS blocker                     | 2,857 (66.9)                      | 1,820 (88.2)                      | 4,677 (73.9)     | < 0.001    |
| Diuretics/natriuretics           | 146 (3.4)                         | 49 (2.4)                          | 195 (3.1)        | 0.024      |
| Others                          | 1,026 (24.0)                      | 581 (28.2)                        | 1,607 (25.4)     | < 0.001    |
| Antidiabetic medication use, n (%) | 1,026 (24.0)                      | 581 (28.2)                        | 1,607 (25.4)     | < 0.001    |

* Defined as an estimated glomerular filtration rate < 60 mL/min/1.73 m² using the closest serum creatinine measured within 60 days of the PRA measurement date.
† RAS suppressors included β-blockers, central acting α-agonists, methyldopa, and direct renin inhibitors.
‡ RAS blockers included angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
§ Diuretics/natriuretics included loop diuretics, thiazide diuretics, calcium channel blockers, and mineralocorticoid receptor blockers.
DBP, diastolic blood pressure; PRA, plasma renin activity; RAS, renin–angiotensin system; SBP, systolic blood pressure; SD, standard deviation.

percentage of individuals with a Charlson comorbidity index of 3 or higher (14% vs. 11%, P < 0.0001 for all). Individuals with SBP ≥ 140 mmHg had a greater usage of all antihypertensive medication classes compared to those with SBP < 140 mmHg.

Those with SBP < 140 mmHg had a higher median PRA level (1.5 vs. 1.1 ng/mL/h) compared with those with SBP ≥ 140 mmHg (Table 1). In those who had available serum studies for analysis, there were no clinically meaningful differences in baseline serum aldosterone, sodium, bicarbonate, phosphorus, albumin, hemoglobin, ferritin, hemoglobin A1C, or cholesterol between those with SBP < 140 mmHg and those with SBP ≥ 140 mmHg (Supplemental Table 2).

Event rates

During 2 years of observation, the overall mortality rate was 7.1% (448 individuals). A total of 798 cardiovascular events occurred. The total number of outcomes was 490 in the SBP ≥ 140 mmHg population and 598 in the SBP < 140 mmHg. Compared with the SBP < 140 mmHg population, the SBP ≥ 140 mmHg population had higher rates of IHE (9.2% vs. 6.1%), CHF (8.2% vs. 4.0%), CED (6.3% vs. 4.0%), and mortality (9.0% vs. 6.1%, P < 0.001 for all). The mortality incidence rate was higher in the SBP ≥ 140 mmHg population compared to SBP < 140 mmHg population (33 vs. 23 deaths per 1,000 person-years; Table 2).

Regression analyses: outcomes in SBP < 140 mmHg versus SBP ≥ 140 mmHg population

In crude models, analysis of the 2-year outcomes showed that patients with SBP ≥ 140 mmHg with measured PRA levels were at greater risk for all outcomes compared with those with measured PRA levels and SBP < 140 mmHg. In adjusted models,
compared with those with SBP < 140 mmHg, individuals with SBP ≥ 140 mmHg were at greater risk for all-cause mortality, combined cardiovascular events, and CHF. Risks for IHE and CED were similar between those with SBP < 140 mmHg and SBP ≥ 140 mmHg. After adjustment for age, sex, race/ethnicity, Charlson comorbidity index, and antihypertensive and diabetogenic medication usage, HRs (95% confidence intervals) were 1.09 (0.90–1.32), 1.38 (1.11–1.71), 1.26 (0.99–1.59), 1.24 (1.08–1.43), and 1.22 (1.00–1.48) for IHE, CHF, CED, combined cardiovascular events, and all-cause mortality, respectively, in the SBP ≥ 140 mmHg group (Tables 2 and 3).

Regression analyses: outcomes by PRA tertile

In subjects with SBP < 140 mmHg, PRA tertiles were 0–0.89 (T1), 0.90–2.64 (T2), and > 2.64 (T3). For SBP ≥ 140 mmHg, PRA tertiles were 0–0.56 (T1), 0.57–1.90 (T2), and > 1.90 (T3). Higher PRA levels were associated with increased HR within the SBP ≥ 140 mmHg group. During the 2-year observation, patients with SBP ≥ 140 mmHg in the highest baseline PRA tertile (T3) had increased risk for combined cardiovascular events compared with those in the lowest PRA tertile (T1) (Table 4). Among the cardiovascular event outcomes, T3 was associated with increased risk for IHE and CHF compared with T1 but not with CED (Table 5). With adjustment for age, sex, race/ethnicity, Charlson comorbidity index, and antihypertensive medication usage, the HRs (95% confidence intervals) were 1.42 (0.99–2.03) and 1.61 (1.12–2.33) for IHE, 1.40 (0.93–2.10) and 2.23 (1.53–3.27) for CHF, 1.10 (0.73–1.68) and 1.06 (0.68–1.66) for CED, 1.23 (0.94–1.59) and 1.43 (1.10–1.86) for combined cardiovascular events, and 1.39 (0.97–1.99) and 1.35 (0.92–1.97) for all-cause mortality for PRA quartiles T2 and T3, respectively, compared to T1 in subjects with SBP ≥ 140 mmHg (Tables 4 and 5).

Among the SBP < 140 mmHg group, there was no relationship between PRA levels and outcomes. The association between elevated PRA and IHE, CHF, CED, combined cardiovascular events, and overall mortality outcomes seen in the SBP ≥ 140 mmHg was not observed.

Discussion

Our study comprising 6,331 individuals with PRA measurements found that higher PRA levels were prognostic of greater cardiovascular outcomes only among patients with SBP ≥ 140 mmHg. In addition, there was a trend toward higher mortality in those with higher PRA and SBP ≥ 140 mmHg. In individuals with SBP < 140 mmHg, there was no relationship between PRA levels and outcomes suggesting that PRA merely reflects physiologic mechanisms to maintain hemodynamics in

| Study outcome | Group | Number of events | Person-years | Incidence rate per 1,000 person-years | Unadjusted HR (95% CI) | Multivariable-adjusted HR (95% CI) |
|---------------|-------|-----------------|--------------|--------------------------------------|------------------------|-----------------------------------|
| Cardiovascular events (combined) | SBP < 140 mmHg | 446 | 11,018 | 40.48 | 1.00 (Reference) | 1.00 (Reference) |
|                | SBP ≥ 140 mmHg | 352 | 5,430 | 64.83 | 1.57 (1.37, 1.81) | 1.24 (1.08, 1.43) |
| Ischemic heart event | SBP < 140 mmHg | 259 | 11,206 | 23.11 | 1.00 (Reference) | 1.00 (Reference) |
|                | SBP ≥ 140 mmHg | 189 | 5,584 | 33.85 | 1.43 (1.19, 1.73) | 1.09 (0.90, 1.32) |
| Congestive heart failure | SBP < 140 mmHg | 169 | 11,289 | 14.97 | 1.00 (Reference) | 1.00 (Reference) |
|                | SBP ≥ 140 mmHg | 170 | 5,626 | 30.22 | 1.97 (1.59, 2.43) | 1.38 (1.11, 1.71) |
| Cerebrovascular accident | SBP < 140 mmHg | 170 | 11,264 | 15.09 | 1.00 (Reference) | 1.00 (Reference) |
|                | SBP ≥ 140 mmHg | 131 | 5,652 | 23.18 | 1.50 (1.19, 1.89) | 1.26 (0.99, 1.59) |

* The adjusted hazards for each study outcome was modeled using the Cox proportional hazards model that included the SBP group variable and the following confounders: age at baseline, sex, race/ethnicity, Charlson comorbidity index, and use of antidiabetic medications, RAS inhibitors, RAS blockers, diuretic/natriuretics, or other antihypertensive medications.
* Only data for incident events were modeled. Patients with a prevalent event of each study outcome were excluded from that model.

CI, confidence interval; HR, hazard ratio; RAS, renin–angiotensin system; SBP, systolic blood pressure.
cular events with 61% increased risk for IHD and over 2-fold risk in the highest PRA tertile compared with the lowest tertile after adjustment for multiple confounders including medication usage. Traditional factors including higher blood pressure, diabetes, older age, and black race were also associated with an increased risk for combined cardiovascular events and all-cause mortality (results not shown).

### Table 5. Incidence rates and relative risks of cardiovascular events stratified by baseline systolic blood pressure

| Strata                  | Study outcome                | Group       | Number of events | PY | Incidence rate per 1,000 PY | Unadjusted HR (95% CI)        | Adjusted HR (95% CI)          |
|-------------------------|------------------------------|-------------|------------------|----|----------------------------|--------------------------------|--------------------------------|
| **Systolic blood pressure < 140 mmHg** |                              |             |                  |    |                            |                                |                                |
| Cardiovascular events (Combined) |                             | 1st Tertile | 166              | 3,658 | 45.38                        | 1.00 (Reference)                  | 1.00 (Reference)                  |
|                          |                              | 2nd Tertile | 148              | 3,663 | 40.40                        | 0.88 (0.70, 1.10)                  | 1.07 (0.86, 1.35)                  |
|                          |                              | 3rd Tertile | 132              | 3,695 | 35.71                        | 0.77 (0.61, 0.97)                  | 0.92 (0.71, 1.21)                  |
| Ischemic heart event    |                              | 1st Tertile | 93               | 3,718 | 25.01                        | 1.00 (Reference)                  | 1.00 (Reference)                  |
|                          |                              | 2nd Tertile | 82               | 3,721 | 22.04                        | 0.87 (0.65, 1.17)                  | 1.11 (0.82, 1.51)                  |
|                          |                              | 3rd Tertile | 84               | 3,767 | 22.30                        | 0.87 (0.65, 1.17)                  | 1.03 (0.76, 1.39)                  |
| Congestive heart failure|                              | 1st Tertile | 69               | 3,735 | 18.47                        | 1.00 (Reference)                  | 1.00 (Reference)                  |
|                          |                              | 2nd Tertile | 51               | 3,756 | 13.58                        | 0.73 (0.51, 1.05)                  | 0.98 (0.68, 1.42)                  |
|                          |                              | 3rd Tertile | 49               | 3,798 | 12.90                        | 0.69 (0.48, 0.99)                  | 0.87 (0.60, 1.26)                  |
| Cerebrovascular accident|                              | 1st Tertile | 59               | 3,745 | 15.75                        | 1.00 (Reference)                  | 1.00 (Reference)                  |
|                          |                              | 2nd Tertile | 63               | 3,740 | 16.84                        | 1.05 (0.74, 1.50)                  | 1.23 (0.86, 1.78)                  |
|                          |                              | 3rd Tertile | 48               | 3,779 | 12.70                        | 0.79 (0.54, 1.16)                  | 0.91 (0.62, 1.35)                  |
| **Systolic blood pressure ≥ 140 mmHg** |                              |             |                  |    |                            |                                |                                |
| Cardiovascular events (Combined) |                             | 1st Tertile | 116              | 3,790 | 64.80                        | 1.00 (Reference)                  | 1.00 (Reference)                  |
|                          |                              | 2nd Tertile | 115              | 3,799 | 63.92                        | 0.98 (0.76, 1.27)                  | 1.23 (0.94, 1.61)                  |
|                          |                              | 3rd Tertile | 121              | 1,841 | 65.73                        | 1.00 (Reference)                  | 1.00 (Reference)                  |
| Ischemic heart event    |                              | 1st Tertile | 57               | 1,832 | 31.11                        | 1.00 (Reference)                  | 1.00 (Reference)                  |
|                          |                              | 2nd Tertile | 65               | 1,855 | 35.04                        | 1.12 (0.79, 1.60)                  | 1.42 (0.99, 2.03)                  |
|                          |                              | 3rd Tertile | 67               | 1,897 | 35.32                        | 1.12 (0.78, 1.59)                  | 1.61 (1.12, 2.33)                  |
| Congestive heart failure|                              | 1st Tertile | 46               | 1,856 | 24.78                        | 1.00 (Reference)                  | 1.00 (Reference)                  |
|                          |                              | 2nd Tertile | 50               | 1,867 | 26.78                        | 1.07 (0.72, 1.60)                  | 1.40 (0.93, 2.10)                  |
|                          |                              | 3rd Tertile | 74               | 1,903 | 38.89                        | 1.54 (1.06, 2.22)                  | 2.23 (1.53, 3.27)                  |
| Cerebrovascular accident|                              | 1st Tertile | 47               | 1,854 | 25.35                        | 1.00 (Reference)                  | 1.00 (Reference)                  |
|                          |                              | 2nd Tertile | 45               | 1,865 | 24.13                        | 0.94 (0.62, 1.41)                  | 1.10 (0.73, 1.68)                  |
|                          |                              | 3rd Tertile | 39               | 1,932 | 20.19                        | 0.78 (0.51, 1.19)                  | 1.06 (0.68, 1.66)                  |

* The adjusted hazards for each study outcome was modeled using the Cox proportional hazards model that included PRA tertiles and the following confounders: age at baseline, sex, race/ethnicity, Charlson comorbidity index, and use of antidiabetic medications, RAS inhibitors, RAS blockers, diuretic/natriuretics, or other antihypertensive medications.

1 Only data for incident outcomes were modeled. Patients with a prevalent diagnosis of each study outcome were excluded from that model.

2 PRA tertiles were determined within the 2 systolic blood pressure strata. In those with baseline SBP < 140 mmHg, the tertile cutoffs were 0.90 and 2.66 ng/mL/h; in the higher ≥ 140 mmHg strata, tertile cutoffs were 0.55 and 1.90 ng/mL/h.

3 CI, confidence interval; HR, hazard ratio; PRA, plasma renin activity; PY, person-year; RAS, renin–angiotensin system; SBP, systolic blood pressure.
While higher blood pressure was associated with an increased risk for CED, an association between higher PRA levels and CED risk was not observed in our study. Our findings underscore the fact that PRA is a reflection of physiological compensation in normotension, whereas higher PRA levels in those with elevated blood pressure denote a pathophysiologic state.

Our study lends insight into the conflicting findings from past observations. PRA as a prognosticator may have a role only in specific populations. In normotensive individuals, PRA may reflect the normal physiology of RAS activity where high or low PRA represent the mechanisms to maintain hemodynamic pressures for optimal perfusion. This is in contrast to those with high blood pressure or cardiac stress states where elevated PRA may represent inappropriate overactivity of the RAS. Thus, our findings among patients with SBP ≥ 140 mmHg are consistent with prior observations demonstrating elevated PRA and greater cardiovascular and mortality risk in high-risk populations. Previous studies among patients with preexisting cardiovascular disease have demonstrated that PRA is associated with an increased risk of cardiovascular events and all-cause mortality [6–13]. Similar to our observations, prior studies focusing on hypertensive populations have also demonstrated an association between PRA and increased risk of cardiovascular outcomes [1–5].

The negative findings in our SBP < 140 mmHg group are also consistent with past observations that found no relationship with PRA and cardiovascular outcomes. We found that PRA did not have an association with risk of cardiovascular and mortality outcomes among individuals with controlled blood pressure independent of prior diagnosis of HTN [13,17–19]. A prospective community-based study of 803 subjects also found no association between PRA and risk of myocardial infarction and sudden cardiac death. This study excluded anyone with prior diagnosis of HTN, and the majority of those enrolled were normotensive with a mean SBP < 140 mmHg [17]. Similarly, the Anglo-Scandinavian Cardiac Outcomes Trial in a hypertensive population did not find an association between higher baseline PRA and risk of cardiovascular disease and mortality. While baseline blood pressure was > 140/80 mmHg in this cohort, the mean blood pressure at the final visit was < 140/80 mmHg in both arms of this study. Thus, PRA values may have lacked utility in this cohort given the normalization of blood pressure [18,19]. Similar to the negative findings in our SBP < 140 mmHg individuals, studies have consistently shown a lack of predictive value of PRA in those without elevated blood pressure.

PRA is the rate-limiting step of the RAS, and RAS activity is regulated by changes in total body volume and blood pressure in normal physiologic states to maintain hemodynamic stability [24]. PRA is frequently not suppressed among hypertensive individuals and can lead to inappropriate vasoconstriction and cellular injury [2,3,5,14]. In addition to stimulating angiotensin II and aldosterone production, the upstream RAS pathway is also thought to directly cause cellular injury and myocardial remodeling through renin and prorenin receptors [25,26]. Animal studies suggest that prorenin receptor activation leads to increase in transforming growth factor-β1, tumor necrosis factor-α, and fibronectin all of which act as prothrombotic inflammatory markers [25]. Persistently elevated RAS activity is thus thought to lead to vascular, renal, and myocardial injury. We previously found that in a population of over 7,000 subjects, higher PRA levels were associated with prevalent IHD, CHF, and CKD [27,28]. In limited observations, it has been shown that suppression of RAS can prevent vascular injury and end-organ damage [5,29–32].

There may be opportunities to lessen vascular/cellular injury and improve both blood pressure and outcomes by using a PRA-based approach [29–32]. RAS blockade in general has been shown to be beneficial for preventing cardiovascular events and mortality in patients with known IHD, CHF, and HTN [31,33–35]. PRA has also been used to more efficiently and effectively control blood pressure in difficult-to-control hypertensive individuals [16]. Hypertensive individuals have been previously shown to differ in their blood pressure responses to various classes of antihypertensive medications [24,36]. A PRA-guided treatment algorithm led to clinically significant reductions in blood pressure and a decrease in the number of antihypertensive medications used [16]. Low-PRA subjects are presumed to have volume-related HTN, whereas high-PRA subjects are considered to have vasoconstriction-dependent HTN [14]. Low-renin subjects have been shown to not respond well to anti-RAS medications, whereas high-renin subjects have been shown to respond poorly to diuretics [14,16,36]. Moreover, subjects may experience a paradoxical rise in blood pressure when prescribed an antihypertensive medication class not suggested by their PRA level [14]. In evaluating our hypertensive population with PRA levels, we previously found that the lowest PRA quartile had the highest usage of PRA-suppressing medications (i.e., β-blockers and direct renin inhibitors) and the lowest rates of diuretic usage [15]. Prior studies in patients with CHF have shown that elevated PRA levels were significantly associated with cardiovascular and renal outcomes despite patients receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers as optimal treatment regimens [7,8,10]. It would be of interest to further investigate the effects of antihypertensive medications that directly affect renin including direct renin inhibitors on both PRA levels and outcomes in patients with both elevated blood pressure and persistently elevated PRA levels. Given our findings, the inclusion of PRA in HTN management particularly in those with difficult-to-control blood pressure and elevated PRA levels may help to improve both efficiency and efficacy of medication use, and subsequent reduction of PRA may ultimately help to improve cardiovascular and mortality outcomes.

Limitations

There are several potential limitations to our study that may confound interpretation of our findings. The effects of medication usage on PRA levels are a potential confounder in our analyses. The majority of our subjects had PRA levels evaluated while concurrently on antihypertensive medication known to influence PRA levels [37]. It was not possible to have subjects stop antihypertensive medications that affect PRA levels given the retrospective observational nature of our study. However, given the fact that the majority of our population were on multiple medications, there were likely offsetting where some antihypertensive medications raised and others lowered PRA levels in the same subjects. While antihypertensive therapy can variably influence plasma renin levels, the increased risk for cardiovascular events in hypertensive subjects with elevated PRA levels was seen after adjustment and control for antihypertensive medications. While 74% of subjects were on
diuretics, 62% on RAS blockers, and 57% on RAS inhibitors, effects of these medications on PRA levels can also offset each other. However, the use of PRA as a biomarker to predict risk for outcomes in the hypertensive population was not affected by simultaneous medication usage in prior observations [6–8,13].

PRA is generally not considered a routine laboratory test, and confounding by indication may be possible. PRA measurements were ordered during real-world clinical encounters and for various indications as determined by individual providers. Thus, our study findings may not generalize to the entire hypertensive population or the general population. PRA levels in our study subjects were not all obtained at the same time or in a standardized fashion, which may reflect diurnal variations in PRA and not necessarily RAS activity [38]. In addition, subjects likely had different levels of physical activity, dietary salt intake, and had blood samples drawn at various times throughout the day. These factors may all contribute to variability in the PRA levels that we found [38,39]. Given the large sample size of our population, we feel that potential diurnal variations in PRA may have averaged out and lessened the relative differences within our study population. While we excluded patients diagnosed with renovascular HTN (N = 201), we were not fully able to account for those with hyperaldosteronism. In our past observations, we had observed that up to 17% of our patients who had concurrent PRA and serum aldosterone levels drawn met the criteria for hyperaldosteronism based on the aldosterone-to-PRA ratio [40].

We used a single blood pressure measurement to categorize into SBP $\geq 140$ mmHg groups without being able to take into consideration blood pressure variations over time. We did perform a sensitivity analysis obtaining mean blood pressure in both SBP groups and found that the differences in blood pressure between the groups were sustained throughout the observation period. The mean blood pressure throughout the observation period was 140/75 mmHg in the baseline SBP $\geq 140$ mmHg group compared with 127/72 mmHg in the SBP < 140 mmHg group. In addition, we were unable to evaluate or control for additional biomarkers and lifestyle modifications such as tobacco abuse, which may be relevant and influence cardiovascular and mortality outcomes. Potentially relevant laboratory measurements including brain natriuretic peptide, C-reactive protein, and 24-hour urinary excretion of sodium were not available for a majority of our study population. Lastly, we evaluated outcomes for only a 2-year follow-up period but may need to consider long-term outcomes for our study population.

Conclusion

Among a large racially diverse PRA study cohort derived from a routine clinical practice environment, higher PRA levels were associated with increased risk for IHEs and CHF and were associated with a trend toward higher mortality only among individuals with SBP $\geq 140$ mmHg but not in those with SBP $< 140$ mmHg. PRA determination may have a role as a biomarker to prognosticate cardiovascular and mortality outcomes in addition to its role in defining mechanisms of HTN.

Conflicts of interest

All authors have no conflicts of interest to declare.

Acknowledgments

This manuscript is dedicated to the memory of Dr John H. Laragh (1925–2015) and his discoveries of the role of renin in human physiology. His work and his teachings have transformed the way practitioners view and treat hypertension. This study was supported by the Kaiser Permanente Southern California Clinician Investigator Award (J.J.S. PI).

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.krcp.2016.07.004.

References

[1] Blumenfeld JD, Sealey JE, Alderman MH, Cohen H, Lappin R, Catanzaro DF, Laragh JH: Plasma renin activity in the emergency department and its independent association with acute myocardial infarction. Am J Hypertens 13:855–863, 2000
[2] Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH: Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 324: 1098–1104, 1991
[3] Alderman MH, Ooi WL, Cohen H, Madhavan S, Sealey JE, Laragh JH: Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 10:1–8, 1997
[4] Gonzalez MC, Cohen HW, Sealey JE, Laragh JH, Alderman MH: Enduring direct association of baseline plasma renin activity with all-cause and cardiovascular mortality in hypertensive patients. Am J Hypertens 24:1181–1186, 2011
[5] Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Bühler FR: Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 286:441–449, 1972
[6] Verma S, Gupta M, Holmes DT, Xu L, Teoh H, Gupta S, Yusuf S, Lonn EM: Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur Heart J 32:2135–2142, 2011
[7] Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, Barlera S, Maggioni AP, Tognoni G, Cohn JN; Val-HeFT Investigators: The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 25:292–299, 2004
[8] Vergaro G, Emdin M, Iervasi A, Zyw L, Gabutti A, Poletti R, Mamminci C, Giannoni A, Fontana M, Passino C: Prognostic value of plasma renin activity in heart failure. Am J Cardiol 108:246–251, 2011
[9] Rouleau JL, Packer M, Moyé L, de Champlain J, Bichet D, Klein M, Rouleau JR, Sussex B, Arnold JM, Sestier F, Parker JO, McEwan P, Bernstein V, Cuddy TE, Lamas G, Gottlieb SS, McCans J, Nadeau C, Delage F, Wun CCC, Pfeffer MA: Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 24:583–591, 1994
[10] Muhlestein JB, May HT, Bair TL, Prescott MF, Horne BD, White R, Anderson JL: Relation of elevated plasma renin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease. Am J Cardiol 106:764–769, 2010
[11] Masson S, Solomon S, Angelici L, Latini R, Anand IS, Prescott M, Maggioni AP, Tognoni G, Cohn JN; Val-HeFT Investigators: Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail 16:964–970, 2010
[12] Campbell DJ, Nussberger J, Stowasser M, Danser AH, Morganti A, Frandsen E, Ménard J: Activity assays and immunoassays for...
plasma renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem 55:867–877, 2009

[13] Parikh NI, Gona P, Larson MG, Wang TJ, Newton-Cheh C, Levy D, Benjamin EJ, Kannel WB, Vasan RS: Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. Eur Heart J 28:2644–2652, 2007

[14] Alderman MH, Cohen HW, Sealey JE, Laragh JH: Pressor responses to antihypertensive drug types. Am J Hypertens 23:1031–1037, 2010

[15] Sim JJ, Bhandari SK, Shi J, Kalantar-Zadeh K, Rasgon SA, Sealey JE, Laragh JH: Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system. Am J Hypertens 25:379–388, 2012

[16] Egan BM, Basile JN, Rehman SJ, Davis PB, Grob 3rd CH, Riehle JF, Walters CA, Lackland DT, Merial C, Sealey JE, Laragh JH: Plasma renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens 22:792–801, 2009

[17] Meade TW, Cooper JA, Peart WS: Plasma renin activity and ischemic heart disease. N Engl J Med 329:616–619, 1993

[18] Sever PS, Chang CL, Prescott MF, Gupta A, Poulter NR, Whitehouse A, Scanlon M: Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Eur Heart J 33:2970–2979, 2012

[19] Dahlöf B, Sever PS, Poulter NR, Wedel H, Beavers DG, Caufield M, Collins R, Jørgensen J, Wachtell D, Mancia G, O’Brien E, Ostergren J: ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlopidine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366:985–906, 2005

[20] Bhandari SK, Pashayan S, Liu IL, Rasgon SA, Kujubu DA, Tober K, Sim JJ: 25-hydroxyvitamin D levels and hypertension rates. J Clin Hypertens (Greenwich) 13:170–177, 2011

[21] Levey AS, Stevens LA, Schmid CH, Coresh J, Collins R, Jørgensen J, Wachtell D, Mancia G, O’Brien E, Ostergren J: ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlopidine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366:985–906, 2005

[22] Sealey JE: Plasma renin activity and plasma prorenin assays. Clin Chem 37:1811–1819, 1991

[23] Sim JJ, Handler J, Jacobsen SJ, Kanter MH: Systemic implementation: strategies to improve hypertension: the Kaiser Permanente Southern California experience. Can J Cardiol 30:544–552, 2014

[24] Laragh JH: Plasma renin activity and its association with ischemic heart disease, congestive heart failure, and cerebrovascular disease in a large hypertensive cohort. J Clin Hypertens (Greenwich) 16:805–813, 2014

[25] Sim JJ, Shi J, Al-Moomen R, Behayaa H, Kalantar-Zadeh K, Jacobsen SJ: Plasma renin activity and its association with ischemic heart disease, congestive heart failure, and cerebrovascular disease in a large hypertensive cohort. J Clin Hypertens (Greenwich) 16:805–813, 2014

[26] Campbell DJ: Critical review of prorenin and (pro)renin receptor research. Hypertension 51:1259–1264, 2008

[27] Sim JJ, Shi J, Al-Moomen R, Behayaa H, Kalantar-Zadeh K, Jacobsen SJ: Plasma renin activity and its association with ischemic heart disease, congestive heart failure, and cerebrovascular disease in a large hypertensive cohort. J Clin Hypertens (Greenwich) 16:805–813, 2014

[28] Sim JJ, Shi J, Calara F, Rasgon S, Jacobsen S, Kalantar-Zadeh K: Association of plasma renin activity and aldosterone-renin ratio with prevalence of chronic kidney disease: the Kaiser Permanente Southern California cohort. J Hypertens 29:2226–2235, 2011

[29] Atias SA, Case DB, Yu ZY, Laragh JH: Hormonal and metabolic effects of angiotensin converting enzyme inhibitors. Possible differences between enalapril and captopril. Am J Med 77:13–17, 1984

[30] Azizi M, Ménard J, Bissery A, Guyenne TT, Bura-Riviére A, Vaidyanathan S, Camisasca RP: Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 15:3126–3133, 2004

[31] McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, Ford J, Verma A, Lewsey J; Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators: Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 1:17–24, 2008

[32] Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlöf B; Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators: Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 119:530–537, 2009

[33] Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedish K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893–1906, 2003

[34] Dahlöf B, Devereux RB, Jørgensen J, Julius S, Beavers G, de Faire U, Fyhrquist F, Isaksson K, Kober L, Lindholm LH, Nieminen MS, Oparil S, Wedel H; LIFE Study Group: Cardiovascular morbidity and mortality in the Los-antarter Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995–1003, 2002

[35] Cohen JN, Tognoni G; Valsartan Heart Failure Trial Investigators: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667–1675, 2001

[36] Turner ST, Schwartz GL, Chapman AB, Beilteelshees AL, Gums JG, Cooper-Dehoff RM, Boerwinkle E, Johnson JA, Bailey KR: Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens 23:1014–1022, 2010

[37] Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F: Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 40:897–902, 2002

[38] Katz FH, Romfh P, Smith JA: Diurnal variation of plasma aldosterone, cortisol and renin activity in supine man. J Clin Endocrinol Metab 40:125–134, 1975

[39] Nakao Y, Tsuchino T, Matsumoto M, Okuda S, Sakoda T, Ohyanagi M, Masuyama T: The mechanism of distinct diurnal variations of renin-angiotensin system in aorta and heart of spontaneously hypertensive rats. Clin Exp Hypertens 31:625–638, 2009

[40] Sim JJ, Yan EH, Liu IL, Rasgon SA, Kalantar-Zadeh K, Calhoun DA, Derose SF: Positive relationship of sleep apnea to hyper-aldosteronism in an ethnically diverse population. J Hypertens 29:1553–1559, 2011